MDxHealth, Predictive Bio Partner on Bladder Cancer Tests | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today announced it has licensed certain DNA methylation biomarkers to Predictive Biosciences for the development of bladder cancer diagnostics.

Under the deal, Predictive has exclusive rights in the United States to use the biomarkers to develop the tests and will pay MDxHealth upfront and milestone payments as well as royalties on net sales.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.